Understanding the pharmacokinetic and pharmacodyanmic properties of azole antifungals for emerging indications is a challenge for clinical research laboratories when using microbiological test methods. Enhanced activity of the itraconazole metabolite, hydroxyitraconazole, can lead to overestimated concentrations. Similarly, the use of two or more drugs in combination can impair the utility of microbiological test methods.
The specificity of UPLC-MS/MS analysis with the ACQUITY UPLC I-Class PLUS and Xevo TQD provides more accurate result in the measurement of azole antifungal for clinical research.
